BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9740952)

  • 21. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
    Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R;
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma.
    Korsch E; Grote A; Seybold M; Soditt V
    Eur J Pediatr; 1999 Aug; 158(8):685. PubMed ID: 10445353
    [No Abstract]   [Full Text] [Related]  

  • 23. [New drugs in glaucoma therapy].
    Gramer E
    Klin Monbl Augenheilkd; 1998 Jul; 213(1):aA10-2. PubMed ID: 9743931
    [No Abstract]   [Full Text] [Related]  

  • 24. The teardrop sign: a rare dermatological reaction to brimonidine.
    Scruggs JT; Whiteside-Michel J; Brodsky MC
    Br J Ophthalmol; 2000 Jun; 84(6):671-2. PubMed ID: 10896417
    [No Abstract]   [Full Text] [Related]  

  • 25. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
    Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
    J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%.
    Barnes SD; Campagna JA; Dirks MS; Doe EA
    Ophthalmology; 1999 Oct; 106(10):2033-7. PubMed ID: 10519604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
    Greenfield DS; Liebmann JM; Ritch R
    J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allergic reactions to brimonidine in patients treated for glaucoma.
    Blondeau P; Rousseau JA
    Can J Ophthalmol; 2002 Feb; 37(1):21-6. PubMed ID: 11865954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apparent central nervous system depression in infants after the use of topical brimonidine.
    Carlsen JO; Zabriskie NA; Kwon YH; Barbe ME; Scott WE
    Am J Ophthalmol; 1999 Aug; 128(2):255-6. PubMed ID: 10458196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylactic brimonidine before LASIK.
    Uretmen O; Ates H; Andaç K
    J Refract Surg; 2003; 19(5):612. PubMed ID: 14518756
    [No Abstract]   [Full Text] [Related]  

  • 31. Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans.
    Kaufman PF
    Arch Ophthalmol; 1999 May; 117(5):673-4. PubMed ID: 10326968
    [No Abstract]   [Full Text] [Related]  

  • 32. Reversible cicatricial ectropion precipitated by topical brimonidine eye drops.
    Aristodemou P; Baer R
    Ophthalmic Plast Reconstr Surg; 2008; 24(1):57-8. PubMed ID: 18209648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
    Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
    thoe Schwartzenberg GW; Buys YM
    Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of apraclonidine on short-term outcome of glaucoma surgery.
    Azuara-Blanco A; Araujo SV; Lu DW; Lesk MR; Katz LJ; Spaeth GL
    J Glaucoma; 1996 Apr; 5(2):117-9. PubMed ID: 8795743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brimonidine and pupillary diameter.
    Mastropasqua L; Carpineto P; Ciancaglini M
    Ophthalmology; 1998 Aug; 105(8):1352-3. PubMed ID: 9709738
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of topical clonidine versus brimonidine on choroidal blood flow and intraocular pressure during squatting.
    Weigert G; Resch H; Garhofer G; Fuchsjäger-Mayrl G; Schmetterer L
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4220-5. PubMed ID: 17724210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate.
    Becker HI; Walton RC; Diamant JI; Zegans ME
    Arch Ophthalmol; 2004 Jul; 122(7):1063-6. PubMed ID: 15249377
    [No Abstract]   [Full Text] [Related]  

  • 40. Systemic side effects of ophthalmic drops.
    Levy Y; Zadok D
    Clin Pediatr (Phila); 2004; 43(1):99-101. PubMed ID: 14968900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.